Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Current Medical Research and Opinion 27:6, pages 1191-1210.
Read now
Read now
Germán Gómez Briseño & Dolores Mino-León. (2010) Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico. Current Medical Research and Opinion 26:5, pages 1075-1081.
Read now
Read now
I. Migdalis, A. Efthimiadis, St. Pappas, D. Alexopoulos, F. Vlasserou & D. P. Mikhailidis. (2009) Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Current Medical Research and Opinion 25:10, pages 2571-2576.
Read now
Read now
Steven K. Hildemann, Christian Barho, Barbara Karmann, Harald Darius & Christoph Bode. (2008) Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Current Medical Research and Opinion 24:10, pages 2777-2784.
Read now
Read now
CS Derdemezis, TD Filippatos, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opinion on Pharmacotherapy 9:11, pages 1829-1837.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
Minna T Jänis, Reijo Laaksonen & Matej Oresic. (2008) Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. Expert Opinion on Drug Metabolism & Toxicology 4:6, pages 665-680.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Dimitri P Mikhailidis, Efstathios D Pagourelias, Anna I Kakafika, Athanasios Skaperdas, Apostolos Hatzitolios & Asterios Karagiannis. (2007) Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opinion on Pharmacotherapy 8:14, pages 2267-2277.
Read now
Read now
Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis & Dimitri P Mikhailidis. (2007) Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opinion on Therapeutic Targets 11:9, pages 1143-1160.
Read now
Read now
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair & Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, pages 2183-2192.
Read now
Read now
D. P. Mikhailidis, G. C. Sibbring, C. M. Ballantyne, G. M. Davies & A. L. Catapano. (2007) Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Current Medical Research and Opinion 23:8, pages 2009-2026.
Read now
Read now
Mihalis Kalogirou, Vasilis Tsimihodimos, Irene Gazi, Theodosios Filippatos, Vasilis Saougos, Alexandros D. Tselepis, Dimitri P. Mikhailidis & Moses Elisaf. (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Current Medical Research and Opinion 23:5, pages 1169-1176.
Read now
Read now
Irene F Gazi & Dimitri P Mikhailidis. (2006) Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opinion on Therapeutic Targets 10:6, pages 851-866.
Read now
Read now
Stella S. Daskalopoulou & Dimitri P. Mikhailidis. (2006) Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Current Medical Research and Opinion 22:10, pages 2037-2039.
Read now
Read now
Lieske Kuitert. (2006) Introduction: inhaled insulins:potential therapies for diabetes mellitus. Current Medical Research and Opinion 22:sup3, pages S1-S4.
Read now
Read now
Articles from other publishers (22)
Yi‐Chih Lin, Tai‐Shuan Lai, Hon‐Yen Wu, Yu‐Hsiang Chou, Wen‐Chih Chiang, Shuei‐Liong Lin, Yung‐Ming Chen, Tzong‐Shinn Chu & Yu‐Kang Tu. (2020) Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta‐Analysis. Clinical Pharmacology & Therapeutics 108:4, pages 833-843.
Crossref
Crossref
Woohyeun Kim, Yeonyee E. Yoon, Sung-Hee Shin, Jang-Whan Bae, Bum-Kee Hong, Soon Jun Hong, Ki Chul Sung, Seung Hwan Han, Weon Kim, Moo-Yong Rhee, Sang-Hyun Kim, Sang Eun Lee, Min Su Hyon, Gyo-Seung Hwang, Jang Won Son, Jang-Young Kim, Min Kyu Kim, Sang Wook Kim, Jae-Hyeong Park, Jin Ho Shin & Chang Gyu Park. (2018) Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Clinical Therapeutics 40:6, pages 993-1013.
Crossref
Crossref
Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abrignani, Marcello Arca, Pasquale Perrone Filardi, Francesco Perticone, Alberico Catapano, Raffaele Griffo, Federico Nardi, Carmine Riccio, Andrea Di Lenarda, Marino Scherillo, Nicoletta Musacchio, Antonio Vittorio Panno, Giovanni Battista Zito, Mauro Campanini, Leonardo Bolognese, Pompilio Massimo Faggiano, Giuseppe Musumeci, Enrico Pusineri, Marcello Ciaccio, Enzo Bonora, Giorgio Cantelli Forti, Maria Pia Ruggieri, Claudio Cricelli, Francesco Romeo, Roberto Ferrari & Attilio Maseri. (2017) ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy. European Heart Journal Supplements 19:suppl_D, pages D3-D54.
Crossref
Crossref
Furio Colivicchi, Michele Massimo Gulizia, Marcello Arca, Maurizio Giuseppe Abrignani, Gian Piero Perna, Gian Francesco Mureddu, Federico Nardi & Carmine Riccio. (2017) ANMCO Scientific Statement: clinical management of hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal Supplements 19:suppl_D, pages D64-D69.
Crossref
Crossref
Patrick Wainwright, Aidan Ryan, Rasaq Olufadi & Christopher D Byrne. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
12
.
L. Luo, X. Yuan, W. Huang, F. Ren, H. Zhu, Y. Zheng & L. Tang. (2015) Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Internal Medicine Journal 45:5, pages 546-557.
Crossref
Crossref
Harold E. Bays, Scott E. Conard, Lawrence A. Leiter, Steven R. Bird, Robert S. Lowe & Andrew M. Tershakovec. (2011) Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International Journal of Cardiology 153:2, pages 141-147.
Crossref
Crossref
Miyako Kishimoto, Takehiro Sugiyama, Keiichiro Osame, Daisuke Takarabe, Masahide Okamoto & Mitsuhiko Noda. (2011) Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. The Journal of Medical Investigation 58:1,2, pages 86-94.
Crossref
Crossref
G. Derosa, A. D’Angelo, I. G. Franzetti, P. D. Ragonesi, G. Gadaleta, F. Scalise, L. Ciccarelli, M. N. Piccinni & A. F. G. Cicero. (2009) Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. Journal of Clinical Pharmacy and Therapeutics 34:3, pages 267-276.
Crossref
Crossref
Francisco Díaz de Rojas, Trinidad De Frutos, Ana Ponte, Joaquin Mateos Chacón & Gustavo C. Vitale. (2009) Coronary Heart Disease and Dyslipidemia: A Cross-Sectional Evaluation of Prevalence, Current Treatment, and Clinical Control in a Large Cohort of Spanish High-Risk Patients: The PRINCEPS Study. Preventive Cardiology 12:2, pages 65-71.
Crossref
Crossref
Scott E. Conard, Harold E. Bays, Lawrence A. Leiter, Steven R. Bird, Joseph Rubino, Robert S. Lowe, Joanne E. Tomassini & Andrew M. Tershakovec. (2008) Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology 102:11, pages 1489-1494.
Crossref
Crossref
Sofia G. Tsouli, Evangelos N. Liberopoulos, John A. Goudevenos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2007) Should a statin be prescribed to every patient with heart failure?. Heart Failure Reviews 13:2, pages 211-225.
Crossref
Crossref
Arrigo F.G. Cicero, Giuseppe Derosa, Marilisa Bove, Elisa Grandi, Elisa Uliassi, Claudio Borghi & Antonio V. Gaddi. (2008) A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterranean Journal of Nutrition and Metabolism 1:1, pages 33-36.
Crossref
Crossref
Adam P. Levine, Dimitri P. MikhailidisTessa Moross, Karen Benson & Mayur Gor. (2008) Achieving Vascular Risk Factor Targets: A Survey of a London General Practice. Angiology 59:1, pages 36-46.
Crossref
Crossref
M. Florentin, E. N. Liberopoulos & M. S. Elisaf. (2007) Ezetimibe-associated adverse effects: what the clinician needs to know. International Journal of Clinical Practice 62:1, pages 88-96.
Crossref
Crossref
Dimitri P. Mikhailidis. 2008. Vascular Complications in Human Disease. Vascular Complications in Human Disease
179
186
.
Vasilios G. Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Konstantinos Tziomalos, Athanasios Skaperdas, Efstathios Pagourelias, Athina Pirpasopoulou, Asterios Karagiannis & Dimitri P. Mikhailidis. (2007) Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. Lipids 42:11, pages 999-1009.
Crossref
Crossref
Anthony S. Wierzbicki. (2007) Targets - who needs them? Success with statin therapies. International Journal of Clinical Practice 61:8, pages 1239-1242.
Crossref
Crossref
Anthony S Wierzbicki. (2007) How aggressively should cholesterol targets be pursued?. British Journal of Hospital Medicine 68:5, pages 232-233.
Crossref
Crossref
Anna I. Kakafika, Dimitri P. Mikhailidis, Asterios Karagiannis & Vasilios G. Athyros. (2007) The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. The Journal of Clinical Pharmacology 47:5, pages 642-652.
Crossref
Crossref
Irina A. Pikuleva. (2006) Cytochrome P450s and cholesterol homeostasis. Pharmacology & Therapeutics 112:3, pages 761-773.
Crossref
Crossref
Aviram Spernath & Abraham Aserin. (2006) Microemulsions as carriers for drugs and nutraceuticals. Advances in Colloid and Interface Science 128-130, pages 47-64.
Crossref
Crossref